FCP
KZR

Fidelis Capital Partners’s Kezar Life Sciences KZR Stock Holding History

Fidelis Capital Partners’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,727
Closed -$24.6K – 392
2024
Q1 		$24.6K Buy
+2,727
New +$24.8K ﹤0.01% 369

Other funds holding KZR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Fidelis Capital Partners's KZR Position: Q2 2024 in Review

Fidelis Capital Partners sold out of Kezar Life Sciences (KZR) in Q2 2024, closing a stake of 2,727 shares — an estimated $24.6K sold.

Fidelis Capital Partners first reported a position in KZR in Q1 2024 and held it in 1 quarter. The position peaked at $24.6K in Q1 2024. 81 funds tracked by Wall St. Rank hold KZR as of Q2 2024.

  • Fidelis Capital Partners reported no remaining Kezar Life Sciences position as of Q2 2024 after selling out during the quarter.
  • Fidelis Capital Partners sold 2,727 Kezar Life Sciences shares in Q2 2024, an estimated $24.6K.
  • Fidelis Capital Partners first reported a position in Kezar Life Sciences in Q1 2024 and held it in 1 quarter.
  • Fidelis Capital Partners's Kezar Life Sciences position peaked at $24.6K in Q1 2024.
  • 81 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2024.

Based on Fidelis Capital Partners's 13F filing for Q2 2024, filed 13 Aug 2024.